PCOS Renamed PMOS as Experts Say New Name Better Reflects the Condition

Polycystic ovary syndrome, one of the most common hormonal conditions affecting women of reproductive age, has been officially renamed polycystic ovarian metabolic syndrome, or PMOS, following a decision by global medical experts announced this week.

The name change reflects a growing scientific understanding that the condition is primarily a metabolic disorder, not simply a reproductive one. Researchers say the old name, PCOS, led to confusion because many women with the condition do not have visible cysts on their ovaries, and the syndrome's effects extend far beyond the ovaries to include insulin resistance, inflammation, and cardiovascular risk.

The new name, PMOS, is intended to signal to both patients and clinicians that the condition requires a broader approach to diagnosis and treatment. Experts say the change should reduce the number of women who go undiagnosed for years because their symptoms do not fit the traditional picture of the condition.

PMOS affects an estimated 8 to 13 percent of women of reproductive age worldwide, making it one of the most common endocrine disorders. Symptoms include irregular periods, excess androgen levels, weight gain, acne, and fertility challenges. Many women also experience anxiety and depression related to the condition.

Medical organizations in the United States, Europe, and Australia have endorsed the name change. Clinical guidelines are being updated to reflect the new terminology and to emphasize metabolic screening as part of standard care for women with the condition.

Patient advocates said the name change is long overdue. Many women with PMOS said they spent years being told their symptoms were not serious or were related to lifestyle choices rather than a recognized medical condition.

Healthline reported the announcement on May 13, 2026, noting that the change is expected to take effect in medical records and insurance coding systems over the next 12 to 18 months.